Anecortave Impurities

Age-related macular degeneration (ARMD) is one of the ocular illnesses for which angiostatic steroid anecortave acetate (Retaane) has been studied.

Show
per page
Impurity structure Parent Drug Name Name of Impurity Catalogue No. CAS No.
Anecortave Impurity 5-D7 Anecortave

Anecortave Impurity 5-D7

DVE0056 N/A
Methyl 3-Oxo-4-Androsten-17-Carboxylate Anecortave

Methyl 3-Oxo-4-Androsten-17-Carboxylate

VL6520001 2681-55-2

Anecortave Related Compound

It is delivered as a posterior juxta scleral depot using a curved, blunt-tipped cannula.

References

FAQ

What is the mechanism of action of Anecortave?

As an antiangiogenic substance, anecortave acetate works to prevent the formation of blood vessels by reducing extracellular protease production and preventing endothelial cell migration. None of the well-known pharmacological receptors appear to be involved in its angiostatic action.

What is ANECORTAVE ACETATE'S PRECLINICAL EFFICACY?

Anecortave acetate decreased blood vessel growth in 12 in vivo and in vitro models during preclinical research. A rat pup model of retinopathy of prematurity using intravitreal injection revealed a 66% suppression of retinal neovascularization and retinopathy.

is anecortave acetate used for Age-related macular degeneration (AMD)?

Anecortave acetate 15 mg for depot suspension is being tested in four clinical efficacy and safety trials for the treatment of subfoveal CNV in individuals with exudative AMD.